PCT





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:		(11) International Publication Number: WO 94/22305
A01N 33/12, 43/40	A1	(43) International Publication Date: 13 October 1994 (13.10.94)
(21) International Application Number: PCT/EP (22) International Filing Date: 15 March 1994 ((30) Priority Data: 9306806.2 1 April 1993 (01.04.93)	15. 03 .9	CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
 (71) Applicant (for all designated States except AU BB CLK MN MW NZ SD): UNILEVER N.V. [NL/NL/455, NL-3013 AL Rotterdam (NL). (71) Applicant (for AU BB CA GB IE LK MN MW NZ SUNILEVER PLC [GB/GB]; Unilever House, Bl London EC4 4BQ (GB).]; Wee	a With international search report.
(72) Inventors: BELLAMY, Kathryn; 20 High Street, Bedford MK43 7LA (GB). ALCOCK, Robert; Close, St. Ives, Cambs PE17 3QX (GB). LABAI LeslieHUDSON, Ronald, Archie; Bernard Zwee NL-2253 BN Voorschoten (NL).	9 Milt N, Kev	a l
(74) Common Representative: UNILEVER N.V.; Patent P.O. Box 137, NL-3130 AC Vlaardingen (NL).	Divisio	
(54) Title: DISINFECTANT COMPOSITIONS		

(57) Abstract

1

There is provided an aqueous virucidal composition suitable as hospital disinfectant, comprising alkaline material and from 0.01 to 5 % by weight of an alkyl quaternary nitrogen salt, and having a pH in the range of 10-12. This composition was found to be effective for killing non-enveloped viruses such as polio viruses, and for disinfecting heat sensitive medical instruments, such as flexible endoscopes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
88	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Paso	ØU	Hungary	NO	Norway
BG	Bulgaria	Œ	Ireland	NZ	New Zealand
BJ	Benin	π	Italy	PL '	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Konya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	SD	Sudan
CG	Congo		of Kores	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
a	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	и	Liechtenstein	SN	Senegal ·
CN	China	. LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxenbourg	1.C	Togo
cz	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany .	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FT	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Vict Nam
GA	Gabon		-		



DISINFECTANT COMPOSITIONS

FIELD OF THE INVENTION

The invention relates to disinfectant compositions. More specifically, it relates to aqueous disinfectant compositions containing an alkyl quaternary nitrogen salt in the presence of an alkaline component.

The invention is particularly suitable to be used for disinfecting objects and surfaces at locations where contamination is of major concern, such as in hospitals, in the food and beverage industry and in the veterinary field.

PRIOR ART AND BACKGROUND OF THE INVENTION

It is known that compositions comprising a quaternary am15 monium halide and a sodium carbonate can be effectively
used as anti-bacterial disinfectants.

FR-A-2 229 426 (Reusse) discloses an anti-bacterial autobiodegradable disinfectant composition comprising 0.1-0.2% 20 by weight of a quaternary ammonium chloride and 35 -40% by weight of sodium carbonate.

DE-A- 2 512 835 (Milbradt) discloses a granular germicidal disinfecting hospital laundering composition comprising one or more quaternary ammonium compounds and sodium carbonate.

25

It is an object of the present invention to provide an anti-viral composition having low toxicity and low corrosivity.

It is a further object of the invention to provide an antiviral composition which shows effective killing ability with respect to non-enveloped hydrophilic viruses, particularly polio-viruses. It is another object of the invention to provide an anti-viral composition which can be effectively applied as an hospital disinfectant.

It was surprisingly found that these and other objects could be achieved with a composition according to the present invention.



DEFINITION OF THE INVENTION

The present invention relates to the use of an aqueous composition containing an alkaline material selected from alkali metal carbonates and alkali metal hydroxides, and from 0.01 to 5% by weight of an alkyl quaternary nitrogen salt, and having a pH in the range of from 10-12, as an anti-viral agent. Furthermore, the invention provides an aqueous virucidal composition suitable as hospital disinfectants, comprising alkaline material selected from alkali metal carbonates and alkali metal hydroxides, and from 0.01 to 5% by weight of an alkyl quaternary nitrogen salt, and having a pH in the range of 10-12.

DETAILED DESCRIPTION OF THE INVENTION

It is known that aqueous compositions containing alkyl quaternary nitrogen salts, particularly quaternary ammonium compounds exhibit some cleaning and bactericidal activity. However, a disadvantage of these compositions is that they are not able to inactivate uncoated viruses such as polioviruses. It has now been found that addition of an alkaline material selected from alkali metal carbonates and hydroxides, to these compositions such that their pH is raised up to values in the range of 10-12, not only increases the disinfecting characteristics but also has a pronounced effect on the virucidal ability thereof. In this context, an aqueous composition is defined to be a composition containing at least 90% water.

The use of the composition of the invention

The aqueous composition of the invention was found to be very effective when used for killing non-enveloped viruses, in particular polio viruses. The effectiveness of the composition was reduced when it was applied in the presence of serum, but this effect could be overcome by the addition of an alkanol solvent selected from the group of ethanol, isopropanol, and n-propanol.

The product according to the invention is intended for use in high risk areas where contamination is of major concern, such as in human health care, veterinary health care and the food industry. The product is particularly suitable for use as disinfectant of medical instruments, especially of flexible endoscopes and similar heat-sensitive delicate instruments, that may be contaminated with viruses. The reason for this applicability of the product of the invention, is that both its toxicity and its aggressivity to delicate instruments are low.

The quaternary nitrogen salt

The alkyl quaternary nitrogen salt present in the aqueous virucidal composition of the invention may be selected from a broad range of compounds which contain at least one alkyl quaternary nitrogen group, and of which a common characteristic is their surface activity caused by the (at least one) alkyl group present therein. Particularly suitable compounds are ammonium salts, pyridinium salts, and quinolinium salts.

Preferably, the quaternary nitrogen salt is selected from compounds of the formulas (I) or (II):

wherein:

 R_1 is a saturated or unsaturated, branched or linear alkyl group having 10-18 carbon atoms; R_2 , R_3 and R_4 are methyl, benzyl, substituted benzyl, or

saturated or unsaturated, linear or branched alkyl groups having 10-18 carbon atoms;
X is a halide ion.

The level of the alkyl quaternary nitrogen salt present in the aqueous virucidal composition is generally in the range of from 0.01 to 5% by weight, preferably from 0.02 to 1% by weight.

Favourable results, particularly with regard to the
virucidal activity on uncoated viruses, were found when at
least one quaternary ammonium halide is contained in the
composition of the invention, said halide being preferably
a dialkyl quaternary ammonium halide. Furthermore, the
halide in those quaternary ammonium compounds is desirably
a chloride or a bromide.

The alkaline material

Generally, the level of the alkaline material in the composition of the invention is to be such that the pH is in the range of from 10 to 12. Depending on the type of


the range of from 10 to 12. Depending on the type of alkaline material, a suitable level of such material is in the range of from 0.2 to 10% by weight.

Generally alkali metal carbonates and hydroxides are applied as alkaline material in the composition of the inven-

tion. Preferred types of alkaline material for use in the composition of the invention, are sodium carbonate and sodium hydroxide, for reasons of availability.

Anti-viral activity

- It is an essential feature of the disinfectant compositions of the invention that the incorporation of an alkaline salt into a disinfectant containing a surface active quaternary nitrogen compound should bring about an improvement of the anti-viral activity. The anti-viral activity of various
- disinfectant compositions on the polio-virus is assessed using the DVV test, as described in Bundesgesundheits Blatt 25 No 12, 1982, p.297.



The alkanol solvent

The alkanol solvent is not only suitable for restoring the effectiveness of the virucidal composition when applied in the presence of a serum. It can also be effectively applied for avoiding inactivation of the virucidal composition of the invention by organic soil. Suitable types of alkanol compounds are in this respect ethanol, iso-propanol and n-propanol. The alkanol is preferably present in an amount of from 10 to 30% by weight of the virucidal composition.

10

The invention will be further illustrated by the following non-limiting examples wherein parts and percentages are by weight, unless otherwise indicated.

15 In these examples the following abbreviations are used:

BARDAC 22 : dialkyl dimethyl quaternary ammonium

chloride (50% active), ex Lonza

Na₂CO₃

: sodium carbonate

 K_2CO_3

: potassium carbonate

20

Comparative Examples A, B

For the purpose of comparison, the virucidal activity of two different demineralised aqueous disinfectant solutions of BARDAC 22 against the polio-virus type 1 (Mahoney strain), was tested as follows.

Suspension tests were carried out according to the guidelines of the Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (published in: Hygiene and Medicine 9, 177-179 (1984)). The polio-virus was obtained from Natec, Hamburg, and Vero cells (Green Monkey Kidney) were purchased from Flow Laboratories.

The polio-virus was grown in confluent layers of Vero until complete cytophatic effect was observed. Cultures were then frozen and thawed, after which they were centrifuged to

remove cell debris. The supernatant was stored in aliquots at -70 °C. The virus content of the suspension was determined by titration.

Monolayers of Vero cells were cultured in 96 well microtitre plates in a 5% carbon dioxide atmosphere. Tenfold dilutions of virus suspension were made in maintenance medium. One hundred microlitres of each dilution were added to a single well, five replicates of each dilution were made. Cell controls were included on every plate. The plates were incubated at 37 °C in a CO₂ incubator, observed daily and discarded after seven days. The virus titre was calculated from the Kärber formula (Lenette E.H. and Schmidt N.J., Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections, 5th Edition, p.32-35 (1979)).

The suspension tests were carried out at room temperature (20 °C) but, after appropriate contact times of respectively 2 and 5 minutes, dilutions were made in ice-cold medium.


Two suspensions of viruses having known titres of 6.7 and 6.3 as calculated using the Kärber formula $(\log_{10} \text{TCID}_{50}/0.1 \text{ ml}: \log_{10} \text{ of } 50\%$ tissue culture infectuous dose, per 0.1 ml), were used for the tests.

25

One volume of virus suspension was mixed with one volume of distilled water and eight volumes of aqueous disinfectant solution. The mixture was kept at 20 °C for the duration of the contact time applied.

30

After appropriate contact times, samples were taken and an initial 1:100 dilution was made by adding 0.1 ml to 9.9 ml medium, subsequent dilutions being made by adding 0.1 ml to 0.9 ml. All dilutions were made in ice-cold medium, and the tubes containing the dilutions were kept on ice until they were inoculated into cell cultures. One hundred microlitres per well, 5 replicates for each dilution.



The micro-titre plates were incubated at 37 °C in an incubator with a 5% CO₂ atmosphere, and examined daily until they were discarded on day 7. The polio virus titre for each contact time was calculated as before using the Kärber formula. The following results from these suspension tests were found.

	Example	aq.disinfect. solution						Virus titre re	ecovered
	No.		2	contac	cte	1		after contact	time of
10	•							2 min.	5 min.
	A	0.2	%wt	sol.	of	BARDAC	22	6.5	5.9
	В	0.05	%wt	sol.	of	BARDAC	22	6.1	6.5

15 Examples 1-4

Several anti-viral disinfectant compositions according to the present invention were formulated, said compositions being demineralised aqueous solutions containing BARDAC 22 and sodium or potassium carbonate.

20

The virucidal activity of these aqueous solutions against the polio-virus type 1 (Mahoney strain), was tested following the procedure of the suspension test described in Examples A and B. The following results expressed in polio virus titres recovered after the appropriate contact times, and calculated using the Kärber formula, were obtained.

	Example	Aq. disinf. solution	<u>Virus titre</u>	recovered
30	No.	including	after contac	t time of
		•	2 min.	5 min.
	1	0.2% BARDAC 22 + 0.2% Na ₂ CO ₃	≤ ² .5	.≤ 2.5
	2	0.05% BARDAC 22 + 0.2% Na ₂ CO ₃	≤ 2.5	≤ 2.5
	3	0.2% BARDAC 22 + 0.2% K ₂ CO ₃	≤ 2.5	≤ 2.5
35	4	0.05% BARDAC 22 + $0.2%$ K ² CO ₃	≤ 2.5	≤ 2.5

When comparing Examples 1-4 with Comparative Examples A,B, it can be concluded that, at both contact times applied, the aqueous disinfectant solutions of the invention and containing both BARDAC 22 and an alkali metal carbonate achieved a reduction of about 4 in the virus titre, as compared to the test results of the comparative disinfectant solutions containing only BARDAC 22.

CLAIMS

- 1. The use of an aqueous composition containing an alkaline material selected from alkali metal carbonates and alkali metal hydroxides, and from 0.01 to 5% by weight of an alkyl quaternary nitrogen salt, and having a pH in the range of from 10-12, as an anti-viral agent.
- 10 2. Use of the composition according to claim 1 for killing non-enveloped viruses, such as polio-viruses.
- Use of the composition according to claim 1 for disinfecting heat sensitive medical instruments, such as
 flexible endoscopes.
- 4. Aqueous virucidal composition suitable as hospital disinfectant, comprising alkaline material selected from alkali metal carbonates and alkali metal hydroxides, and from 0.01 to 5% by weight of an alkyl quaternary nitrogen salt, and having a pH in the range of 10-12.
- 5. Composition according to claim 4, wherein the quaternary nitrogen salt comprises at least one compound of the 25 formulas (I) or (II):

$$R_1 \xrightarrow{R_2} R_4 \qquad X^- \qquad \qquad (1)$$

 $R_1 \longrightarrow N^+$ (II)

35

15

wherein:

X is a halide ion.

R₁ is a saturated or unsaturated, branched or linear alkyl group having 10-18 carbon atoms;

R₂, R₃ and R₄ are methyl, benzyl, substituted benzyl, or saturated or unsaturated, linear or branched alkyl groups having 10-18 carbon atoms;

- 6. Composition according to claim 5, wherein the quaternary nitrogen salt comprises at least one quaternary ammonium halide of the formula (I).
 - 7. Composition according to claim 6, wherein the quaternary ammonium halide is a dialkyl quaternary ammonium halide.
 - 8. Composition according to claim 6 or 7, wherein the quaternary ammonium halide contains a halide selected from the group consisting of chloride and bromide.
- 20 9. Composition according to any of claims 4-8, wherein the composition comprises from 0.02 to 1% by weight of the alkyl quaternary nitrogen salt.
- 10. Composition according to any of claims 4-9, wherein 25 the composition comprises from 0.2 to 10% by weight of the alkaline material.
- 11. Composition according to any of claims 4-10, wherein the composition comprises from 10 to 30 % by weight of an 0 alkanol selected from the group consisting of ethanol, isopropanol and n-propanol.

35 *******

INTERNATIONAL SEARCH REPORT ication No PCT/EP 94/00821 A. CLASSIFICATION OF SUBJECT MATTER IPC 5 A01N33/12 A01N43 IPC 5 A01N43/40 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 5 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. US,A,3 941 696 (J.L. MELNICK ET AL.) 2 1-5,9,10 March 1976 see column 2, line 3 - line 10 see column 3, line 50 - line 53 X,P CHEMICAL ABSTRACTS, vol. 119, no. 19, 1-10 8 November 1993, Columbus, Ohio, US; abstract no. 195159q, M. KAGEYAMA ET AL. 'inactivation activity of various disinfectants against infectious bursal disease virus' see abstract & CHIKUSAN NO KENKYU vol. 47, no. 8 , 1993

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
A document defining the general state of the art which is not considered to be of particular relevance E earlier document but published on or after the international filing date L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) O document referring to an oral disclosure, use, exhibition or other means P document published prior to the international filing date but later than the priority date claimed	 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '&' document member of the same patent family
Date of the actual completion of the international search 20 June 1984	Date of mailing of the international search report 0 1, 07, 94
Name and mailing address of the ISA	Authorized officer

Form PCT/ISA/210 (second sheet) (July 1992)

NI. - 2280 HV Ripswijk

Fax: (+31-70) 340-3016

European Patent Office, P.B. 5818 Patentlaan 2

Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

pages 929 - 931

Decorte, D

INTERNATIONAL SEARCH REPORT

Intication No PCT/E: 34/00821

`		PCT/E94	/00821
C1(Coupum	tuon) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
X	FR,A,2 139 074 (ROHM AND HAAS) 5 January 1973 see page 3, line 6 - line 8 see page 14; table 2 see claims 1,6		4-10
X .	DE,A,27 11 577 (CHEMED CORP.) 21 September 1978 see page 25; examples a-d		4-11
A	DE,A,40 05 784 (SCHÜLKE & MAYR) 29 August 1991 see page 1, line 18 - line 30		1
A	EP,A,O 190 797 (J.K. VOIT) 13 August 1986 see claim 1	•	11
			·
			-
			_
-			
	•		
			·

INTERNATIONAL SEARCH REPORT

ion on patent family members

Interi and pation No PCT/EP 54/00821

				1 . 0 . 7 2 . 3 17 0002 1		
Patent document cited in search report	Publication date	Patent family member(s)		Publication date		
US-A-3941696	02-03-76	US-A-	4043911	23-08-77		
FR-A-2139074	05-01-73	AU-A- BE-A- CA-A- DE-A- GB-A-	4277272 783920 965678 2225109 1348744	29-11-73 27-11-72 08-04-75 14-12-72 20-03-74		
DE-A-2711577	21-09-78	NONE				
DE-A-4005784	29-08-91	US-A-	5185145	09-02-93		
EP-A-0190797	13-08-86	NONE				